1. 115PDetection of actionable variants in various cancer types reveals value of whole-genome sequencing over in-silico whole-exome and hotspot panel sequencing. (7th November 2019) Authors: Ramarao-Milne, K P; Patch, A-M; Nones, K; Koufariotis, R; Newell, F; Addala, V R; Kondrashova, O; Mukhopadhyay, P; Kazakoff, S H; Lakis, V; Holmes, O; Leonard, C; Wood, S; Xu, C; Pearson, J V; Hollway, G; Waddell, N Journal: Annals of oncology Issue: Volume 30(2019)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1188PIdentification of prognostic and predictive factors for durvalumab efficacy by modeling of tumor response and overall survival (OS) in patients with non-small cell lung cancer (NSCLC). (23rd October 2018) Authors: Zheng, Y; Narwal, R; Jin, C; Baverel, P; Gupta, A; Mukhopadhyay, P; Higgs, B W; Roskos, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 83OImpact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC. (13th April 2019) Authors: Ouwens, M; Darilay, A; Zhang, Y; Mukhopadhyay, P; Mann, H; Ryan, J; Dennis, P A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗